Gold Standard Treatment for Sudden Sensorineural Hearing Loss
In this case study, a man with hearing loss after a stroke benefits from hyperbaric oxygen therapy and steroid treatments.
Tag: SSNHL
All
Latest
All
Latest
Sensorion, Cochlear Ltd Start Pilot Study for SENS-401
Sensorion and Cochlear Limited (ASX:COH), announce the initiation of a pilot study of the first-in-class small molecule drug SENS-401 (Arazasetron) in patients scheduled for cochlear implantation.
All
Latest
Contralateral Routing of Signal: A Status Report 2019
Douglas Beck & Virginia Ramachandran examine the various forms of unilateral hearing loss and review the various treatment methods with particular emphasis on the effectiveness of CROS and BiCROS hearing aid fittings.
Sensorion Receives European Medicines Agency Approval for PIP on Hearing Loss Treatment
SENS-401 is under development in the treatment of Sudden Sensorineural Hearing Loss (or SSNHL).
Read More
Osteoporosis May Increase Risk of Sudden Sensorineural Hearing Loss, Study Shows
The researchers found that 0.8% of those with osteoporosis and 0.5% of adults in the control group without the condition experienced sudden sensorineural hearing loss. This means that people with osteoporosis have a 40% increased risk of developing a sudden sensorineural hearing.
Read More
Frequency Therapeutics Announces Positive Results from Hearing Restoration Drug Trial
The trial assessed the safety of a single dose of FX-322 given by intratympanic administration in adult patients with stable sensorineural hearing loss (SSHL) who had a medical history consistent with either chronic noise exposure or idiopathic sudden sensorineural hearing loss
Read More
Acoustic Neuromas and Sudden Sensorineural Hearing Loss: A Case Study
Patients presenting with sudden sensorineural hearing loss (SSNHL) may be thought of as one of the few true “emergencies of the ear” presented to hearing care professionals. Here is a case study that highlights the importance of the MRI when evaluating SSNHL.
Read More
Sensorion and Pasteur Institute to Collaborate on Gene Therapy Products
Sensorion announced a letter of intent with Pasteur Institute in Paris to exclusively negotiate a framework agreement to obtain the exclusive licenses to develop and commercialize gene therapy product candidates for restoration, treatment, and prevention of hearing loss disorders. They will collaborate on several lead programs to correct monogenic forms of hereditary hearing loss including, among others, the Usher syndrome type 1 and otoferlin deficiency, according to the announcement.
Read More
High-pressure Oxygen Therapy May Help Treat Sudden Deafness, Says ‘JAMA’ Study
This study combined the results of 19 studies, including three randomized clinical trials, and suggests a greater benefit of adding the hyperbaric oxygen therapy may be associated with those patients who have severe to profound hearing loss and who failed to recover after standard medical treatment.
Read More
Sensorion Receives Approval for SENS-401 Phase 2 Clinical Trial
The randomized, double-blind, placebo-controlled Phase 2 study will be conducted across 50 sites in Europe, the US, Canada, Israel, and Turkey, and enroll approximately 260 patients.
Read More
NEW WEBINAR: Depression, Hearing Loss, and Treatment with Hearing Aids
Victor Bray, PhD, reviews the research on depression and hearing loss, treatment effects, risk factors, and how you can screen for depression in this free webinar sponsored by Hamilton CapTel®. He also postulates a future in which hearing healthcare professionals will be called on to assist mental health specialists in the treatment of depressed individuals.
Read More
Sensorion Presents SENS-401 Data at Ci2018 Conference
Data from the presented studies showed that SENS-401 protected inner ear function and enhanced sensory hair cell survival in preclinical models of acoustic trauma and, separately, cisplatin infusion.
Read More
Sensorion Presents SENS-401 Data at ARO 2018 MidWinter Meeting
SENS-401, R-azasetron besylate, is a drug candidate that aims to protect and preserve inner ear tissue when lesions are present that can cause progressive or sequelar hearing impediments.
Read More
Drug to Treat Sudden Deafness Granted Orphan Drug Status by EMA
Strekin AG, Basal, Switzerland, announced that the European Medicines Agency (EMA) has granted orphan drug designation for the use of STR001 in the treatment of sudden sensorineural hearing loss, or sudden deafness.
Read More
Auris Medical Begins Phase 3 Trial for Sudden Deafness Drug
Auris Medical announced it has initiated patient enrollment in the ASSENT Phase 3 clinical trial of AM-111, a drug for treating idiopathic sudden sensorineural hearing loss, or sudden deafness. The drug must be administered within 72 hours after onset of hearing loss.
Read More
Auris Medical Enrolls First Patient in HEALOS Trial of Hearing Loss Drug
Auris Medical Holding AG, a Swiss biopharmaceutical company, announced enrollment of the first patient into the HEALOS clinical trial to test the drug, AM-111, as a therapy for sudden hearing loss. The trial involves 255 patients suffering from acute severe to profound hearing loss within 72 hours from onset.
Read More
People with Osteoporosis at Higher Risk for Sudden Deafness
According to a retrospective cohort study carried out in Taiwan, people with osteoporosis are at higher risk for sudden deafness.
Read MoreRehabilitative Aspects of ISSNHL
Amplification and bone conduction options for those with idiopathic sudden sensorineural hearing loss (ISSNHL), and why counseling is the key to success.
Read More